Autologous Platelet Transfusion in Alloimmunized Patients with Acute Leukemia

Overview

Journal Ann Hematol

Specialty Hematology

Date 1995 Oct 1

PMID 7578522

Authors

I Funke

M Wiesneth

K Koerner

M Cardoso

E Seifried

B Kubanek

H Heimpel

Affiliations

Soon will be listed here.

Abstract

Seventy-eight transfusions of autologous platelets were given to eight alloimmunized patients receiving curative chemotherapy for acute leukemia. Platelets were collected at regeneration of hematopoiesis after a chemotherapy cycle, cryopreserved with 5% dimethylsulfoxide in liquid nitrogen, and retransfused during bone marrow aplasia following the next treatment cycle. The in vitro platelet recovery after freezing, thawing, and washing was 85 +/- 4%. The in vivo corrected count increment 1 h after autologous platelet transfusions was 11 +/- 5 x 10(9)/l. With the exception of moderate urticaria and slight nausea each after one transfusion, no immediate or chronic side effects occurred. The bleeding time was shortened and hemorrhage during bone marrow aplasia was prevented in all alloimmunized patients by autologous platelet transfusions.

References

Schiffer C, Aisner J, Wiernik P . Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med. 1978; 299(1):7-12. DOI: 10.1056/NEJM197807062990102. View

Gmur J, Burger J, Schanz U, Fehr J, Schaffner A . Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991; 338(8777):1223-6. DOI: 10.1016/0140-6736(91)92098-m. View

Ten Haaft M, van den Berg-Loonen P, van Rhenen D . Prevention of primary HLA class I allo-immunization with leucocyte-poor blood components produced without the use of platelet filters. Vox Sang. 1992; 63(4):257-61. DOI: 10.1111/j.1423-0410.1992.tb01231.x. View

Kickler T, Braine H, Ness P . The predictive value of crossmatching platelet transfusion for alloimmunized patients. Transfusion. 1985; 25(4):385-9. DOI: 10.1046/j.1537-2995.1985.25485273823.x. View

Pegels J, Bruynes E, Engelriet C, von dem Borne A . Serological studies in patients on platelet- and granulocyte-substitution therapy. Br J Haematol. 1982; 52(1):59-68. DOI: 10.1111/j.1365-2141.1982.tb03861.x. View

Wiesneth M, Freudenberg J, Platow S, Kalinova J, Vogel M, Kubanek B . Comparison of plateletpheresis with two different cell separators using 100 identical donors. Beitr Infusionsther. 1991; 28:201-3. View

Friedberg R, Donnelly S, Boyd J, Gray L, Mintz P . Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood. 1993; 81(12):3428-34. View

van Marwijk Kooy M, van Prooijen H, Moes M, Akkerman J . Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood. 1991; 77(1):201-5. View

GAYDOS L, Freireich E, Mantel N . The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962; 266:905-9. DOI: 10.1056/NEJM196205032661802. View

10.

McFarland J, Anderson A, Slichter S . Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol. 1989; 73(3):380-6. DOI: 10.1111/j.1365-2141.1989.tb07757.x. View

11.

Schiffer C, Lichtenfeld J, Wiernik P, MARDINEY Jr M, Joseph J . Antibody response in patients with acute nonlymphocytic leukemia. Cancer. 1976; 37(5):2177-82. DOI: 10.1002/1097-0142(197605)37:5<2177::aid-cncr2820370504>3.0.co;2-d. View

12.

EERNISSE J, Brand A . Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol. 1981; 9(1):77-83. View

13.

Aster R, LEVIN R, Cooper H, Freireich E . COMPLEMENT-FIXING PLATELET ISO-ANTIBODIES IN SERUM OF TRANSFUSED PERSONS. CORRELATION OF ANTIBODIES WITH PATELET SURVIVAL IN THROMBOCYTOPENIC PATIENTS. Transfusion. 1964; 4:428-40. DOI: 10.1111/j.1537-2995.1964.tb02902.x. View

14.

Valeri C . Hemostatic effectiveness of liquid-preserved and previously frozen human platelets. N Engl J Med. 1974; 290(7):353-8. DOI: 10.1056/NEJM197402142900702. View

15.

Yankee R, Grumet F, Rogentine G . Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med. 1969; 281(22):1208-12. DOI: 10.1056/NEJM196911272812202. View

16.

Odink J, Sprokholt R . Platelet preservation. III. The influence of dimethylsulfoxide and cooling conditions on serotonin uptake velocity and response to hypotonic stress of human platelets. Thromb Haemost. 1976; 36(1):192-9. View

17.

Brand A, Claas F, Voogt P, Wasser M, EERNISSE J . Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang. 1988; 54(3):160-6. DOI: 10.1111/j.1423-0410.1988.tb03892.x. View

18.

Lok S, Kaushansky K, Holly R, Kuijper J, Oort P, Grant F . Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994; 369(6481):565-8. DOI: 10.1038/369565a0. View

19.

Oksanen K . Leukocyte-depleted blood components prevent platelet refractoriness in patients with acute myeloid leukemia. Eur J Haematol. 1994; 53(2):100-7. DOI: 10.1111/j.1600-0609.1994.tb01872.x. View

20.

Schiffer C, Buchholz D, Aisner J, WOLFF J, Wiernik P . Frozen autologous platelets in the supportive care of patients with leukemia. Transfusion. 1976; 16(4):321-9. DOI: 10.1046/j.1537-2995.1976.16476247052.x. View